Aclaris Therapeutics, Inc. (ACRS)
3.44
-0.06
(-1.71%)
USD |
NASDAQ |
Nov 20, 16:00
3.445
0.00 (0.00%)
After-Hours: 20:00
Aclaris Therapeutics Enterprise Value : 406.25M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 406.25M |
| November 19, 2026 | 415.30M |
| November 18, 2026 | 415.30M |
| November 17, 2026 | 397.21M |
| November 16, 2026 | 431.14M |
| November 13, 2026 | 478.65M |
| November 12, 2026 | 490.72M |
| November 11, 2026 | 542.00M |
| November 10, 2026 | 513.34M |
| November 09, 2026 | 526.91M |
| November 06, 2026 | 475.63M |
| November 05, 2026 | 431.90M |
| November 04, 2026 | 442.45M |
| November 03, 2026 | 451.50M |
| November 02, 2026 | 460.55M |
| October 30, 2026 | 486.19M |
| October 29, 2026 | 489.21M |
| October 28, 2026 | 484.68M |
| October 27, 2026 | 459.04M |
| October 26, 2026 | 459.04M |
| October 23, 2026 | 453.01M |
| October 22, 2026 | 465.08M |
| October 21, 2026 | 462.06M |
| October 20, 2026 | 456.03M |
| October 19, 2026 | 412.29M |
| Date | Value |
|---|---|
| October 16, 2026 | 382.12M |
| October 15, 2026 | 413.80M |
| October 14, 2026 | 397.21M |
| October 13, 2026 | 410.78M |
| October 12, 2026 | 430.39M |
| October 09, 2026 | 465.08M |
| October 08, 2026 | 459.04M |
| October 07, 2026 | 400.22M |
| October 06, 2026 | 445.47M |
| October 05, 2026 | 531.44M |
| October 02, 2026 | 549.54M |
| October 01, 2026 | 552.56M |
| September 30, 2026 | 680.76M |
| September 29, 2026 | 648.57M |
| September 28, 2026 | 669.54M |
| September 25, 2026 | 630.39M |
| September 24, 2026 | 662.55M |
| September 23, 2026 | 645.77M |
| September 22, 2026 | 710.09M |
| September 21, 2026 | 689.12M |
| September 18, 2026 | 679.33M |
| September 17, 2026 | 665.35M |
| September 16, 2026 | 654.16M |
| September 15, 2026 | 682.82M |
| September 14, 2026 | 698.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.741B |
| Corcept Therapeutics, Inc. | 6.596B |
| Veru, Inc. | 9.969M |
| Johnson & Johnson | 678.48B |
| Eli Lilly & Co. | 1.313T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.51M |
| Revenue (Quarterly) | 1.481M |
| Total Expenses (Quarterly) | 19.99M |
| EPS Diluted (Quarterly) | -0.1238 |
| Gross Profit Margin (Quarterly) | 10.80% |
| Profit Margin (Quarterly) | -1.25K% |
| Earnings Yield | -17.15% |
| Normalized Earnings Yield | -17.12 |